ADIL.OQ
Latest Trade
1.92USDChange
-0.14(-6.80%)Volume
63,089Today's Range
-
2.1052 Week Range
-
4.00As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 2.06 |
|---|---|
Open | 2.07 |
Volume | 63,089 |
3M AVG Volume | 13.88 |
Today's High | 2.10 |
Today's Low | 1.92 |
52 Week High | 4.00 |
52 Week Low | 1.00 |
Shares Out (MIL) | 14.39 |
Market Cap (MIL) | 27.63 |
Forward P/E | -2.16 |
Dividend (Yield %) | -- |
Adial Pharmaceuticals Says U.S. FDA Reactivated Adial'S U.S. IND Application, Lifted Clinical Hold From AD04
Adial Pharmaceuticals And Biolab Sciences Enter Into Distribution Agreement For Covid-19 Antibody Tests
Adial Pharmaceuticals Inc says On May 26, Reached Understanding On Terms To Purchase Covid-19 IgG / IgM Rapid Test Kits
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of medications for the treatment of addictions and related disorders. Its lead investigational drug product is AD04. AD04 is being developed for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist. AD04 is being designed to be used for the treatment of other addictive disorders, such as opioid use disorder, obesity, smoking, and other drug addictions.
Industry
Biotechnology & Drugs
Contact Info
1180 SEMINOLE TRAIL, SUITE 495
CHARLOTTESVILLE, VA
22901
United States
+1.434.4229800
https://www.adialpharma.com/Executive Leadership
William B. Stilley
President, Chief Executive Officer, Director
Kevin Schuyler
Vice Chairman, Lead Independent Director
Joseph Truluck
Chief Financial Officer, Chief Operating Officer, Treasurer, Secretary
Bankole A. Johnson
Chief Medical Officer
J. Kermit Anderson
Independent Director
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 3.85 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -119.91 |
Return on Equity (TTM) | -107.23 |
* ADIAL PHARMACEUTICALS ANNOUNCES APPROVAL TO COMMENCE LANDMARK ONWARD!" PIVOTAL PHASE 3 TRIAL IN POLAND
* ADIAL PHARMACEUTICALS FILES PROSPECTUS SUPPLEMENT RELATED TO OFFERING OF 2.8 MILLION COMMON SHARES - SEC FILING Source: https://bit.ly/2BRIRoN Further company coverage:
* ADIAL PHARMACEUTICALS AND BIOLAB SCIENCES ENTER INTO DISTRIBUTION AGREEMENT FOR COVID-19 ANTIBODY TESTS
* ADIAL PHARMACEUTICALS INC - ON MAY 26, REACHED UNDERSTANDING ON TERMS TO PURCHASE COVID-19 IGG / IGM RAPID TEST KITS
* ADIAL PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $50 MILLION – SEC FILING Source text for Eikon: https://bit.ly/2VsiyNq Further company coverage:
* ADIAL PHARMACEUTICALS PROVIDES UPDATE ON ONWARD9 PHASE 3 PIVOTAL TRIAL
* ADIAL PHARMACEUTICALS INC. - ADIAL PHARMACEUTICALS ANNOUNCES MODIFICATIONS TO PHASE 3 PIVOTAL TRIAL OF AD04 TO PROTECT SUBJECTS FROM COVID-19
* ADIAL PHARMACEUTICALS INC. - ADIAL PHARMACEUTICALS COMMENCES PHASE 3 TRIAL OF AD04 FOR ALCOHOL USE DISORDER
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.